Lipocine Inc (LPCN) Actualités

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 PR Newswire SALT LAKE CITY...

Form 8-K - Current report

Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Announces FDA Labeling Changes for Testosterone Products PR Newswire SALT LAKE CITY, March 12, 2025...

Form 8-K - Current report

Form 8-K - Current report

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Lipocine Receives Updated Regulatory Guidance on LPCN 1154 PR Newswire SALT LAKE CITY, Feb. 6, 2025 SALT LAKE...

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with...

Form 8-K - Current report